市場調査レポート
商品コード
1410829
止血検査の世界市場 - 市場規模(セグメント別)、シェア、規制、償還、予測(~2033年)Hemostasis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
止血検査の世界市場 - 市場規模(セグメント別)、シェア、規制、償還、予測(~2033年) |
出版日: 2023年12月18日
発行: GlobalData
ページ情報: 英文
納期: 即納可能
|
当レポートでは、世界の止血検査市場について調査分析し、各セグメントの市場規模、市場動向、競合情勢、COVID-19の影響などの情報を提供しています。
市場モデルの主な内容は以下の通りです。
上市済みの止血検査と進化する競合情勢
世界、地域、国レベルの市場固有の考察
医療制度の概要を含む真の全体像を把握することで、市場の理解を促進します。また、市場参入セグメントでは、償還政策や規制情勢についての情報を提供し、市場力学をより深く掘り下げることができます。
対象企業
Not Applicable
Not Applicable
Hemostasis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Hemostasis tests market for the year 2020 and beyond. Prothrombin (PT) and Activated Prothrombin (aPTT) tests represent the most widely used Hemostasis tests. These devices are frequently utilized for coagulation testing prior to surgery. Specifically sources indicate that preoperative coagulation testing occurs in approximately 39%-55% of cases and in many instances is considered to be un-indicated and performed when bleeding history is negative. PT tests are also frequently used for monitoring of patients taking vitamin K antagonists such as warfarin, phenprocoumon, and acenocoumarol.
Hemostasis tests includes Prothrombin Time Point of Care (POC) Tests, Prothrombin Time Laboratory Tests, Activated Partial Thromboplastin Time Point of Care (POC) Tests, Activated Partial Thromboplastin Time Laboratory Tests, D-Dimer Point of Care (POC) Tests, D-Dimer Laboratory Tests.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Hemostasis tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens AG, Diagnostica Stago SAS, Werfen Life Group SAU, Bio-Rad Laboratories Inc, bioMerieux SA, Quidelortho Corp, Danaher Corp, Revvity Inc, and others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable